Azithromycin/Chloroquine + Sulfadoxine-Pyrimethamine/Chloroquine
Phase 2/3Completed 0 watching 0 views this week📈 Rising
64
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
PLASMODIUM FALCIPARUM MALARIA
Conditions
PLASMODIUM FALCIPARUM MALARIA
Trial Timeline
Sep 1, 2003 → Jan 1, 2005
NCT ID
NCT00074841About Azithromycin/Chloroquine + Sulfadoxine-Pyrimethamine/Chloroquine
Azithromycin/Chloroquine + Sulfadoxine-Pyrimethamine/Chloroquine is a phase 2/3 stage product being developed by Pfizer for PLASMODIUM FALCIPARUM MALARIA. The current trial status is completed. This product is registered under clinical trial identifier NCT00074841. Target conditions include PLASMODIUM FALCIPARUM MALARIA.
Hype Score Breakdown
Clinical
22
Activity
15
Company
9
Novelty
7
Community
8
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00084240 | Phase 2/3 | Terminated |
| NCT00074841 | Phase 2/3 | Completed |
Competing Products
13 competing products in PLASMODIUM FALCIPARUM MALARIA
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KLU156 + Coartem | Novartis | Phase 3 | 77 |
| artemether:lumefantrine (2.5 mg:30 mg) | Novartis | Phase 2/3 | 65 |
| INE963 | Novartis | Phase 2 | 52 |
| KAE609 + Piperaquine Phosphate | Novartis | Phase 1 | 33 |
| KAE609 + SoC (Coartem) + KLU156 | Novartis | Phase 2 | 52 |
| KAF156 + Coartem + Lumefantrine Solid Dispersion Formulation | Novartis | Phase 2 | 52 |
| Artemether-lumefantrine | Novartis | Phase 3 | 77 |
| INE963 + KAE609 (Cipargamin) + SoC (Coartem) + KLU156 | Novartis | Phase 2 | 52 |
| KAF156 + LUM-SDF + Coartem | Novartis | Phase 2 | 52 |
| Ferroquine (SSR97193) + Placebo + artesunate | Sanofi | Phase 2 | 51 |
| Ferroquine SSR97193 + Artefenomel | Sanofi | Phase 2 | 51 |
| Artefenomel (OZ439) + Ferroquine (SSR97193) | Sanofi | Phase 2 | 51 |
| Meplazumab for Injection + Sterile normal saline (0.9%) | Pacific Biosciences | Phase 1 | 25 |